Inhalation Delivered RNA Aptamer for Therapeutics against SARS-CoV2
Min-Sun SongiD, Jiehua ZhouiD, Alberto HerreraiD, Peter Baines, John J. RossiiD
Abstract
The continual emergence and re-emergence of infectious diseases has led to a pressing need for the development of swift and targeted therapeutic interventions. SARS-CoV-2, the causative agent of COVID-19, is a prime example of such a rapidly spreading virus[1]. The global crisis caused by this virus has propelled researchers to explore and adopt novel techniques in the hopes of effectively combating its spread[2]. One such innovative approach is the use of aptamers--single-stranded RNA molecules that can bind targets with high specificity.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inhibition of SARS-CoV-2 Infection in Human Airway Epithelium with a Xeno-Nucleic Acid Aptamer
N. Razi, W. Li, … J. J. DeStefano·bioRxiv·Sep 27, 2023
- A SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection in vitro by an RBD independent mechanism
A. Schmitz, A. Weber, … G. Mayer·bioRxiv·Dec 23, 2020
- A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19
Adi Idris, Alicia M. Davis, … Kevin V. Morris·Molecular TherapyPeer-reviewed·May 13, 2021
- In silico design and validation of high-affinity RNA aptamers for SARS-CoV-2 comparable to neutralizing antibodies
Yanqing Yang, Lulu Qiao, … Ruhong Zhou·eLifePeer-reviewed·Jul 14, 2026
- Xeno-nucleic Acid (XNA) 2'-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding
I. Alves Ferreira-Bravo, J. J. DeStefano·bioRxiv·Jul 13, 2021
- Highly potent antisense oligonucleotides (ASOs) targeting the SARS-CoV-2 RNA genome
Vita Dauksaite, Ali Taş, … Anton Jan van Zonneveld·bioRxiv·Nov 28, 2022